Trial Profile
A single-centre, prospective, longitudinal study to evaluate the clinical response and association of drug exposure with toxicity in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jul 2017
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 02 Dec 2015 New trial record